Cargando…

Improving Communication in Outpatient Consultations in People With Cirrhosis: The Development of a Question Prompt List (QPL)

Liver health professionals have difficulty discussing liver cirrhosis and its prognosis with patients and families. Question Prompt Lists (QPLs), which are evidence-based lists of “recommended questions,” may improve communication but need to be designed specifically for the target population. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Low, Joseph T.S., Davis, Sarah, Greenslade, Lynda, Carroll, Cathy, Craig, Rachel, Wilson, Jo, Clancy, Jennifer-Louise, Marshall, Aileen, Thorburn, Douglas, Stone, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	LIVER, PANCREAS & BILIARY TRACT: Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664949/ https://www.ncbi.nlm.nih.gov/pubmed/32301836 http://dx.doi.org/10.1097/MCG.0000000000001347

Ejemplares similares

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study
por: Iavarone, Massimo, et al.
Publicado: (2023)

Systemic inflammation as fuel for acute liver injury in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2021)

Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021)

Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points
por: Leo, M., et al.
Publicado: (2022)

Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury
por: Lleo, Ana, et al.
Publicado: (2022)

Chronic liver disease-related mortality in diabetes before and during the COVID-19 in the United States
por: Kim, Donghee, et al.
Publicado: (2023)

COVID-19 vaccination among cirrhotics in Italy: High coverage and effectiveness of 3 doses versus 2 in preventing breakthrough infection and hospitalization
por: Stroffolini, Tommaso, et al.
Publicado: (2023)

Mass Spectrometry-Based (GeLC-MS/MS) Comparative Proteomic Analysis of Endoscopically (ePFT) Collected Pancreatic and Gastroduodenal Fluids
por: Paulo, Joao A, et al.
Publicado: (2012)

Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤25 mm in Size and ≤1 Involved Lymph Nodes
por: Tummala, Pavan, et al.
Publicado: (2013)

A Pilot Study to Develop a Diagnostic Test for Pancreatic Ductal Adenocarcinoma Based on Differential Expression of Select miRNA in Plasma and Bile
por: Cote, Gregory A, et al.
Publicado: (2014)

The Question‐prompt list (QPL): Why it is needed in the Indian oncology setting?
por: Chawak, Shweta, et al.
Publicado: (2020)

Transition in the etiology of liver cirrhosis in Japan: a nationwide survey
por: Enomoto, Hirayuki, et al.
Publicado: (2019)

The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan
por: Enomoto, Hirayuki, et al.
Publicado: (2020)

Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis
por: Sakaida, Isao, et al.
Publicado: (2016)

Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis
por: Kotani, Kohei, et al.
Publicado: (2023)

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
por: Sayiner, Mehmet, et al.
Publicado: (2017)

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
por: Chayama, Kazuaki, et al.
Publicado: (2017)

Endoscopic Retrograde Cholangiopancreatography (ERCP) in Patients With Liver Cirrhosis: Analysis of Trends and Outcomes From the National Inpatient Sample Database
por: Solanki, Shantanu, et al.
Publicado: (2022)

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience
por: Waldenström, Jesper, et al.
Publicado: (2016)

LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest
por: Morton, Jennifer P., et al.
Publicado: (2010)

Cholecystectomy or Gallbladder In Situ After Endoscopic Sphincterotomy and Bile Duct Stone Removal in Chinese Patients
por: Lau, James Y.W., et al.
Publicado: (2006)

Liver Sinusoidal Endothelial Cell Lectin, LSECtin, Negatively Regulates Hepatic T-Cell Immune Response
por: Tang, Li, et al.
Publicado: (2009)

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
por: Takehara, Tetsuo, et al.
Publicado: (2018)

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
por: Naganuma, Atsushi, et al.
Publicado: (2019)

Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan
por: Sakaida, Isao, et al.
Publicado: (2015)

Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study)
por: Sakaida, Isao, et al.
Publicado: (2020)

Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus
por: Tahata, Yuki, et al.
Publicado: (2023)

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study
por: Takehara, Tetsuo, et al.
Publicado: (2020)

Algorithm to determine the outcome of patients with acute liver failure: a data-mining analysis using decision trees
por: Nakayama, Nobuaki, et al.
Publicado: (2012)

Butein inhibits ethanol-induced activation of liver stellate cells through TGF-β, NFκB, p38, and JNK signaling pathways and inhibition of oxidative stress
por: Szuster-Ciesielska, Agnieszka, et al.
Publicado: (2012)

Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study
por: Izumi, Namiki, et al.
Publicado: (2012)

High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma
por: Kumada, Takashi, et al.
Publicado: (2013)

Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study
por: Nishiguchi, Shuhei, et al.
Publicado: (2013)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas
por: Shimizu, Takayuki, et al.
Publicado: (2013)

Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy
por: Chen, I-Pei, et al.
Publicado: (2013)

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study
por: Hayashi, Norio, et al.
Publicado: (2013)

Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients
por: Murata, Kazumoto, et al.
Publicado: (2013)

Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease
por: Tokushige, Katsutoshi, et al.
Publicado: (2013)

Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation?
por: Takaki, Akinobu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_elrtaj0ckccp5b6esl82d9e4f6